Despite EGFR-TKIs having led to a dramatic improvement in clinical outcomes in EGFR mutated NSCLC, the majority of patients eventually experience resistance to EGFR-TKIs, regardless of the lines of treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.